melanoma Archives -

Regeneron seeks CheckMate in immuno-oncology play

Phil Taylor CheckMate Pharma, head and neck cancer, immuno-oncology, M&A, melanoma, Oncology, Regeneron, toll-like receptor agonist, vidutolimod 0 Comment

Regeneron has agreed an all-cash deal to acquire CheckMate Pharmaceuticals, adding immune activator vidutolimod to its cancer immunotherapy

Regeneron seeks CheckMate in immuno-oncology play

https://pharmaphorum.com/news/regeneron-seeks-checkmate-in-immuno-oncology-play/

News/ News/ Oncology

Sour taste for Nektar as bempegaldesleukin flunks ph3 test

Phil Taylor Bristol-Myers Squibb, immuno-oncology, melanoma, Nektar Therapeutics, Oncology 0 Comment

Four years ago, Bristol-Myers Squibb paid $1.85 billion upfront to claim rights to Nektar’s bempegaldesleukin, setting it up

Sour taste for Nektar as bempegaldesleukin flunks ph3 test

https://pharmaphorum.com/news/sour-taste-for-nektar-as-bempegaldesleukin-flunks-ph3-test/

Market Access/ News/ News

NICE gives Keytruda parity with Opdivo for adjuvant melanoma

Phil Taylor adjuvant, HEOR, melanoma, Merck & Co, NHS, NICE 0 Comment

After three years of availability via the Cancer Drugs Fund (CDF), MSD’s checkpoint inhibitor Keytruda has now been

NICE gives Keytruda parity with Opdivo for adjuvant melanoma

https://pharmaphorum.com/news/after-stint-on-cdf-nice-makes-keytruda-routine-for-adjuvant-melanoma/

News/ News/ Oncology

Merck claims another adjuvant okay from FDA for Keytruda

Phil Taylor adjuvant, fda, Keytruda, melanoma, Merck & Co, regulatory approval 0 Comment

Merck & Co’s strategy of pushing Keytruda earlier in the treatment pathway for cancers has secured anther victory,

Merck claims another adjuvant okay from FDA for Keytruda

https://pharmaphorum.com/news/merck-claims-another-adjuvant-okay-from-fda-for-keytruda/

News/ News/ Oncology

BioNTech takes its first cancer vaccine into phase 2

Phil Taylor BioNTech, BNT111, cancer vaccine, immuno-oncology, melanoma, Oncology 0 Comment

It would be easy to forget that back in 2019, BioNTech was an early-stage biotech firmly focused on

BioNTech takes its first cancer vaccine into phase 2

https://pharmaphorum.com/news/biontech-takes-its-first-cancer-vaccine-bnt111-into-phase-2/

News/ News/ Oncology

IO Biotech raises $155m to develop breakthrough cancer vaccine

Richard Staines IO Biotech, melanoma, Novo Seeds, Oncology, R&D, vaccine 0 Comment

IO Biotech, an oncology specialist formed and backed by Denmark’s Novo Holdings, has raised €127 million ($155 million)

IO Biotech raises $155m to develop breakthrough cancer vaccine

https://pharmaphorum.com/news/io-biotech-raises-155m-to-develop-breakthrough-cancer-vaccine/

News/ News/ News/ Oncology/ R&D

Regeneron pairs with BioNTech on melanoma immunotherapy

Phil Taylor BioNTech, cancer vaccine, checkpoint inhibitors, immuno-oncology, Libtayo, melanoma, Regeneron 0 Comment

Regeneron and Sanofi’s PD-1 inhibitor Libtayo will be tested in tandem with a cancer vaccine developed by BioNTech

Regeneron pairs with BioNTech on melanoma immunotherapy

https://pharmaphorum.com/news/regeneron-pairs-with-biontech-on-melanoma-immunotherapy/

Market Access/ News/ News/ News/ Oncology

Roche’s Tecentriq claims melanoma OK, but don’t expect a sales surge

Phil Taylor Bristol-Myers Squibb, checkpoint inhibitors, immuno-oncology, melanoma, Oncology, Opdivo, Roche, Tecentriq, Yervoy 0 Comment

Roche’s checkpoint inhibitor Tecentriq has been cleared for another new use in the US – in melanoma –

Roche’s Tecentriq claims melanoma OK, but don’t expect a sales surge

https://pharmaphorum.com/news/roches-tecentriq-claims-melanoma-ok-but-dont-expect-a-sales-surge/

News/ News/ News/ Oncology/ R&D

Merck builds case for six-week Keytruda dosing as FDA starts review

Phil Taylor immuno-oncology, Keytruda, melanoma, Merck & Co, Oncology 0 Comment

Merck & Co’s checkpoint inhibitor Keytruda can be given half as often and still retain its efficacy, according

Merck builds case for six-week Keytruda dosing as FDA starts review

https://pharmaphorum.com/news/merck-builds-case-for-six-week-keytruda-dosing-as-fda-starts-review/

Trending

melanoma

Login